Clindamycin

Generic Name: Clindamycin

Brand Names: Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃ClN_₂O_₅S

CAS Number: 18323-44-9

Unique Ingredient Identifier: 3U02EL437C

Background: Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.

Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.

Indication: In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purpose, or as a triple combination therapy with benzoyl peroxide and adapalene. Clindamycin is also indicated as a vaginal cream, suppository, or gel for the treatment of bacterial vaginosis in non-pregnant females.

Clindamycin is used for antimicrobial prophylaxis against Viridans group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.

Associated Conditions: Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci

Clinical Trials

Clostridioides Difficile Controlled Human Infection Model

Not Applicable

Not yet recruiting

Conditions: C. Difficile
C. Difficile Infection
Controlled Human Infection

Interventions: Other: encapsulated 10^4 CFU toxigenic. C. difficile spores
Drug: Vancomycin
Drug: Clindamycin

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 60

Registration Number: NCT06702345

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Zuid Holland, Netherlands

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
Drug: CABTREO Topical Gel
Drug: Placebo Control

First Posted Date: 2024-11-05

Last Posted Date: 2024-11-05

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 382

Registration Number: NCT06673641

Locations: 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Phase 4

Recruiting

Conditions: Community Acquired Pneumonia in Children

Interventions: Drug: Ampicillin for Injection
Drug: Ceftriaxone for Injection
Drug: Amoxicillin
Drug: Ampicillin / Sulbactam Injection
Drug: Amoxicillin-clavulanate
Drug: Clindamycin
Drug: Cefprozil
Drug: Levofloxacin

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-20

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 236

Registration Number: NCT06494072

Locations: 🇺🇸
Childrens Wisconsin, Milwaukee, Wisconsin, United States

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Phase 4

Not yet recruiting

Conditions: Bacteremia
Endocarditis

Interventions: Drug: Clindamycin
Drug: Doxycycline

First Posted Date: 2024-05-20

Last Posted Date: 2024-06-17

Lead Sponsor: University of Santiago de Compostela

Target Recruit Count: 150

Registration Number: NCT06422221

Locations: 🇪🇸
Santiago de Compostela University Hospital, Santiago De Compostela, A Coruña, Spain

Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection

Phase 4

Recruiting

Conditions: Prosthetic-joint Infection
Infection; Knee, Joint
Infection Hip

Interventions: Drug: Rifampicin and levofloxacin
Drug: Clindamycin

First Posted Date: 2023-12-15

Last Posted Date: 2023-12-15

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 316

Registration Number: NCT06172010

Locations: 🇳🇱
Alrijne Ziekenhuis, Leiderdorp, Netherlands
🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇳🇱
Martini ziekenhuis, Groningen, Netherlands

and more 10 locations

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Active, not recruiting

Conditions: Streptococcal Sepsis
Infection, Bacterial
Necrotizing Soft Tissue Infection
Infection, Bloodstream
Invasive Group A Beta-Haemolytic Streptococcal Disease
Streptococcal Toxic Shock Syndrome

First Posted Date: 2023-11-13

Last Posted Date: 2023-11-13

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 1000

Registration Number: NCT06126263

Locations: 🇺🇸
National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda, Maryland, United States

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Amivantamab IV
Drug: Amivantamab SC
Drug: Lazertinib
Drug: Doxycycline
Drug: Minocycline
Drug: Clindamycin
Drug: Chlorhexidine
Other: Noncomedogenic skin moisturizer
Other: Ruxolitinib
Other: Tacrolimus

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 300

Registration Number: NCT06120140

Locations: 🇹🇷
Adana City Hospital, Adana, Turkey
🇹🇷
Gulhane Training and Research Hospital, Ankara, Turkey
🇨🇳
Sichuan Cancer Hospital, Chengdu, China

and more 90 locations